Cargando…
Development of Interpretable Predictive Models for BPH and Prostate Cancer
BACKGROUND: Traditional methods for deciding whether to recommend a patient for a prostate biopsy are based on cut-off levels of stand-alone markers such as prostate-specific antigen (PSA) or any of its derivatives. However, in the last decade we have seen the increasing use of predictive models tha...
Autores principales: | Bermejo, Pablo, Vivo, Alicia, Tárraga, Pedro J, Rodríguez-Montes, JA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345941/ https://www.ncbi.nlm.nih.gov/pubmed/25780348 http://dx.doi.org/10.4137/CMO.S19739 |
Ejemplares similares
-
BPH and prostate cancer risk
por: Miah, Saiful, et al.
Publicado: (2014) -
Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH
por: Saito, Motoaki, et al.
Publicado: (2014) -
Marker assisted pyramiding of Bph6 and Bph9 into elite restorer line 93–11 and development of functional marker for Bph9
por: Wang, Yang, et al.
Publicado: (2017) -
Inflammasomes are important mediators of prostatic inflammation associated with BPH
por: Kashyap, Mahendra, et al.
Publicado: (2015) -
Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)
por: Sciacqua, L. V., et al.
Publicado: (2023)